Scholarlink

<p>The management of unresectable stage III non-small cell lung cancer (NSCLC) continues to evolve with the integration of immunotherapy and targeted agents into treatment paradigms. The PACIFIC trial established consolidation durvalumab following concurrent chemoradiotherapy (CRT) as the standard of care&#xa0;in many settings. However, emerging evidence challenges the one-size-fits-all approach, particularly for molecularly defined subsets and specific patient populations. This debate article examines the evolving landscape of non-surgical stage III NSCLC management, presenting evidence-based arguments for refining treatment strategies based on molecular biomarkers, novel immunotherapy combinations, and alternative sequencing approaches.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The evolution of non-surgical management in stage III non-small cell lung cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月3日

查看全文
  • Milit S. Patel,
  • Alessandro Hammond,
  • Edward Christopher Dee,
  • Puneeth Iyengar

摘要

The management of unresectable stage III non-small cell lung cancer (NSCLC) continues to evolve with the integration of immunotherapy and targeted agents into treatment paradigms. The PACIFIC trial established consolidation durvalumab following concurrent chemoradiotherapy (CRT) as the standard of care in many settings. However, emerging evidence challenges the one-size-fits-all approach, particularly for molecularly defined subsets and specific patient populations. This debate article examines the evolving landscape of non-surgical stage III NSCLC management, presenting evidence-based arguments for refining treatment strategies based on molecular biomarkers, novel immunotherapy combinations, and alternative sequencing approaches.